Nantahala Capital Management, LLC is an SEC-registered investment adviser based in New Canaan, CT that reports managing 3 hedge funds on Form ADV. It reports $3.1 billion in regulatory assets under management. Its private funds, of all types, hold $1.3 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +10.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +100.7% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $3.1 billionForm ADV Item 5.F
- Gross assets of private funds
- $1.3 billionAll private fund types, Form ADV
- Hedge funds managed
- 33 private funds in total
- Employees
- 14Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 158081
- Latest Form ADV
- 09/14/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +16.7% | +14.8% |
| Q1 2026 | -5.5% | -4.6% |
| Q4 2025 | +13.2% | +2.4% |
| Q3 2025 | +25.6% | +7.8% |
| Q2 2025 | +14.5% | +10.4% |
| Q1 2025 | -6.1% | -4.5% |
| Q4 2024 | +5.1% | +2.1% |
| Q3 2024 | +13.2% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 143 share positions ($1,774,065,159) reported by Nantahala Capital Management, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Bioventus Inc4.93%
- Bancorp Inc Del3.98%
- Evolus Inc2.82%
- Peloton Interactive Inc2.54%
- Eton Pharmaceuticals Inc2.54%
- Hilton Grand Vacations Inc2.49%
- Amneal Pharmaceuticals Inc2.40%
- LB Pharmaceuticals Inc2.32%
- Savara Inc2.08%
- Fossil Group Inc2.04%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Bioventus Inc | $87,516,649 | 4.93% | 6,420,884 | +7.01% |
| Bancorp Inc Del | $70,567,740 | 3.98% | 1,465,277 | +18.18% |
| Evolus Inc | $49,957,520 | 2.82% | 6,244,690 | +11.47% |
| Peloton Interactive Inc | $45,131,731 | 2.54% | 9,044,435 | +77.03% |
| Eton Pharmaceuticals Inc | $45,079,855 | 2.54% | 875,507 | -25.55% |
| Hilton Grand Vacations Inc | $44,244,946 | 2.49% | 1,276,542 | +23.56% |
| Amneal Pharmaceuticals Inc | $42,611,185 | 2.40% | 2,115,749 | -6.74% |
| LB Pharmaceuticals Inc | $41,234,474 | 2.32% | 1,074,374 | +2.04% |
| Savara Inc | $36,827,740 | 2.08% | 7,137,159 | +2.30% |
| Fossil Group Inc | $36,168,691 | 2.04% | 5,505,128 | Unchanged |
| Ultragenyx Pharmaceutical In | $35,159,574 | 1.98% | 2,339,293 | New |
| Avalo Therapeutics Inc | $32,841,582 | 1.85% | 2,142,308 | +15.04% |
| Mimedx Group Inc | $32,203,228 | 1.82% | 6,910,564 | +44.95% |
| Abeona Therapeutics Inc | $28,405,875 | 1.60% | 5,410,643 | +5.34% |
| Establishment Labs Hldgs Inc | $28,270,479 | 1.59% | 440,556 | +31.18% |
| Titan Machy Inc | $26,255,554 | 1.48% | 1,137,589 | +0.40% |
| Adma Biologics Inc | $25,982,464 | 1.46% | 2,590,475 | +9.77% |
| Fox Factory Hldg Corp | $25,783,838 | 1.45% | 1,403,584 | +7.09% |
| Distribution Solutions GRP I | $25,605,572 | 1.44% | 733,684 | +48.34% |
| Fulcrum Therapeutics Inc | $24,328,802 | 1.37% | 6,575,352 | +20.10% |
| Xtant Med Hldgs Inc | $24,286,710 | 1.37% | 68,394,000 | Unchanged |
| Gogo Inc | $24,111,803 | 1.36% | 11,214,792 | +28.94% |
| Aura Biosciences Inc | $23,909,844 | 1.35% | 3,807,300 | +29.02% |
| Regeneron Pharmaceuticals | $23,613,286 | 1.33% | 31,141 | New |
| Jack In The Box Inc | $22,879,312 | 1.29% | 1,730,659 | +0.12% |
| RMR Group Inc | $22,651,112 | 1.28% | 1,252,827 | +9.14% |
| Herbalife LTD | $22,406,111 | 1.26% | 1,847,165 | +66.54% |
| Opus Genetics Inc | $22,116,516 | 1.25% | 4,569,528 | +49.26% |
| Zevra Therapeutics Inc | $21,535,164 | 1.21% | 1,963,096 | +9.21% |
| Anteris Technologies Global | $21,443,700 | 1.21% | 2,759,807 | -18.43% |
| Inspire Med SYS Inc | $20,324,838 | 1.15% | 293,034 | +8.74% |
| Abivax SA | $19,679,730 | 1.11% | 198,745 | +48.58% |
| Agomab Therapeutics NV | $19,400,247 | 1.09% | 1,747,770 | +11.45% |
| Ridenow Group Inc | $18,901,338 | 1.07% | 3,436,607 | +5.00% |
| Rayonier Advanced Matls Inc | $17,821,055 | 1.00% | 2,236,017 | +31.71% |
| Vor Biopharma Inc | $17,775,768 | 1.00% | 931,644 | +10.25% |
| Tango Therapeutics Inc | $17,643,043 | 0.99% | 707,136 | +41.24% |
| Biocryst Pharmaceuticals Inc | $17,503,471 | 0.99% | 2,101,257 | +10.52% |
| Mineralys Therapeutics Inc | $17,335,704 | 0.98% | 689,841 | -15.92% |
| Geron Corp | $17,064,446 | 0.96% | 13,873,533 | +13.48% |
| Keros Therapeutics Inc | $16,986,581 | 0.96% | 1,490,051 | +5.65% |
| Benitec Biopharma Inc | $16,775,670 | 0.95% | 1,677,567 | +12.71% |
| Obsidian Therapeutics Inc | $16,473,199 | 0.93% | 1,199,796 | New |
| Jefferson Capital Inc | $15,752,582 | 0.89% | 825,607 | +10.08% |
| Adc Therapeutics SA | $15,342,945 | 0.86% | 12,576,184 | +2.03% |
| Camping World Hldgs Inc | $14,947,582 | 0.84% | 2,977,606 | +16.72% |
| Janux Therapeutics Inc | $14,814,732 | 0.84% | 857,334 | +5.85% |
| Planet Fitness Master Issuer | $14,508,396 | 0.82% | 343,638 | +23.17% |
| Verastem Inc | $14,327,712 | 0.81% | 1,779,840 | -0.70% |
| Usana Health Sciences Inc | $14,304,217 | 0.81% | 988,543 | +22.03% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 32 new positions, 17 sold out, 61 increased, 13 reduced and 37 unchanged.
Number of positions (a count, not dollars)
- New positions32
- Increased61
- Unchanged37
- Reduced13
- Sold out17
New positions
| Stock | Value | Shares |
|---|---|---|
| Ultragenyx Pharmaceutical In | $35,159,574 | 2,339,293 |
| Regeneron Pharmaceuticals | $23,613,286 | 31,141 |
| Obsidian Therapeutics Inc | $16,473,199 | 1,199,796 |
| Research Alliance Corp III | $11,913,000 | 1,100,000 |
| Attovia Therapeutics Inc | $9,618,625 | 561,180 |
| Ishares TR | $9,573,033 | 34,449 |
| Service Pptys TR Com New | $8,930,934 | 1,386,791 |
| Entera Bio LTD | $8,744,107 | 3,004,848 |
| Dyne Therapeutics Inc | $6,161,076 | 382,438 |
| Damora Therapeutics Inc Com SHS | $5,915,840 | 278,000 |
| Dicks Sporting Goods Inc | $5,371,600 | 40,000 |
| Tcgx Acquisition Corp | $5,166,505 | 412,990 |
| Inflarx NV | $4,849,106 | 2,693,948 |
| Pharvaris N V | $4,758,000 | 150,000 |
| Sagimet Biosciences Inc | $4,661,690 | 471,831 |
| Fractyl Health Inc | $4,060,282 | 7,458,269 |
| Jatt III Acquisition Corp | $2,755,000 | 250,000 |
| Cue Biopharma Inc | $2,484,788 | 96,049 |
| Viatris Inc | $2,356,849 | 133,005 |
| Femasys Inc | $1,732,633 | 802,145 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Uniqure NV | $20,987,700 | 455,660 |
| Integer Hldgs Corp | $10,401,172 | 111,302 |
| Fractyl Health Inc | $8,968,058 | 11,289,096 |
| Amylyx Pharmaceuticals Inc | $8,740,845 | 486,684 |
| Damora Therapeutics Inc | $7,230,780 | 278,000 |
| RH | $6,043,285 | 36,686 |
| First Tracks Biotherapeutics | $5,030,000 | 250,000 |
| Chime Finl Inc | $3,524,997 | 172,119 |
| Rallybio Corp | $3,014,752 | 188,422 |
| Entrada Therapeutics Inc | $2,212,232 | 300,575 |
| Alx Oncology Hldgs Inc | $1,552,500 | 750,000 |
| BRC Inc | $1,395,460 | 1,257,171 |
| Vyne Therapeutics Inc | $1,301,400 | 2,000,000 |
| Snap Inc | $888,000 | 200,000 |
| Spar Group Inc | $545,926 | 660,688 |
| Biomx Inc | $215,232 | 634,995 |
| Guardforce Ai Co LTD | $5,420 | 154,205 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Peloton Interactive Inc | +3,935,440 | +77.03% | $45,131,731 | 9,044,435 |
| Bancorp Inc Del | +225,390 | +18.18% | $70,567,740 | 1,465,277 |
| Mimedx Group Inc | +2,143,012 | +44.95% | $32,203,228 | 6,910,564 |
| Herbalife LTD | +738,011 | +66.54% | $22,406,111 | 1,847,165 |
| Hilton Grand Vacations Inc | +243,372 | +23.56% | $44,244,946 | 1,276,542 |
| Distribution Solutions GRP I | +239,103 | +48.34% | $25,605,572 | 733,684 |
| Opus Genetics Inc | +1,508,169 | +49.26% | $22,116,516 | 4,569,528 |
| Establishment Labs Hldgs Inc | +104,726 | +31.18% | $28,270,479 | 440,556 |
| Abivax SA | +64,986 | +48.58% | $19,679,730 | 198,745 |
| Bioventus Inc | +420,605 | +7.01% | $87,516,649 | 6,420,884 |
| Gogo Inc | +2,517,061 | +28.94% | $24,111,803 | 11,214,792 |
| Aura Biosciences Inc | +856,270 | +29.02% | $23,909,844 | 3,807,300 |
| Tango Therapeutics Inc | +206,477 | +41.24% | $17,643,043 | 707,136 |
| Evolus Inc | +642,669 | +11.47% | $49,957,520 | 6,244,690 |
| Avalo Therapeutics Inc | +280,058 | +15.04% | $32,841,582 | 2,142,308 |
| Rayonier Advanced Matls Inc | +538,291 | +31.71% | $17,821,055 | 2,236,017 |
| Fulcrum Therapeutics Inc | +1,100,312 | +20.10% | $24,328,802 | 6,575,352 |
| Zai Lab LTD | +130,000 | +65.00% | $8,692,200 | 330,000 |
| Planet Fitness Master Issuer | +64,638 | +23.17% | $14,508,396 | 343,638 |
| Usana Health Sciences Inc | +178,469 | +22.03% | $14,304,217 | 988,543 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Imax Corp | -506,512 | -76.98% | $8,302,036 | 151,497 |
| Eton Pharmaceuticals Inc | -300,444 | -25.55% | $45,079,855 | 875,507 |
| Duolingo Inc | -43,549 | -51.92% | $5,742,707 | 40,328 |
| Anteris Technologies Global | -623,528 | -18.43% | $21,443,700 | 2,759,807 |
| Forrester Resh Inc | -350,400 | -45.90% | $4,754,159 | 413,046 |
| Mineralys Therapeutics Inc | -130,640 | -15.92% | $17,335,704 | 689,841 |
| Amneal Pharmaceuticals Inc | -153,002 | -6.74% | $42,611,185 | 2,115,749 |
| Trisalus Life Sciences Inc | -500,000 | -50.00% | $2,155,000 | 500,000 |
| Silence Therapeutics PLC | -184,347 | -13.69% | $12,704,857 | 1,162,384 |
| Industrial Logistics Pptys T | -235,000 | -21.15% | $6,220,686 | 876,153 |
| Inhibikase Therapeutics Inc | -750,000 | -27.76% | $4,011,078 | 1,951,863 |
| Codexis Inc | -1,025,744 | -28.31% | $3,611,038 | 2,597,869 |
| Verastem Inc | -12,570 | -0.70% | $14,327,712 | 1,779,840 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Peloton Interactive, Inc. | 13G amendment | 6.17% | 26,118,235 | Nov 13, 2026 | SEC.gov ↗ |
| Grace Therapeutics, Inc. | 13G amendment | 7.45% | 1,654,393 | Nov 13, 2026 | SEC.gov ↗ |
| TELA Bio, Inc. | 13G amendment | 14.5% | 6,545,596 | Nov 13, 2026 | SEC.gov ↗ |
| Fulcrum Therapeutics, Inc. | 13G amendment | 8.62% | 6,575,352 | Nov 13, 2026 | SEC.gov ↗ |
| Tessera Defense & Homeland Security Inc. | 13G amendment | 2.72% | 73,054 | Nov 13, 2026 | SEC.gov ↗ |
| Fractyl Health, Inc. | 13G amendment | 6.91% | 938,982 | Nov 13, 2026 | SEC.gov ↗ |
| Gogo Inc. | 13G amendment | 8.28% | 11,214,792 | Nov 13, 2026 | SEC.gov ↗ |
| Yarrow Bioscience, Inc. | 13G amendment | 0.46% | 39,198 | Nov 13, 2026 | SEC.gov ↗ |
| Curis, Inc. | 13G amendment | 9.99% | 258,739 | Nov 13, 2026 | SEC.gov ↗ |
| DarioHealth Corp. | 13G amendment | 9.99% | 979,036 | Nov 13, 2026 | SEC.gov ↗ |
| Senti Biosciences Holdings, Inc. | 13G amendment | 4.1% | 1,332,000 | Nov 13, 2026 | SEC.gov ↗ |
| Usana Health Sciences Inc | 13G | 5.35% | 988,543 | Nov 13, 2026 | SEC.gov ↗ |
| AEON Biopharma, Inc. | 13G | 9.99% | 5,048,027 | Nov 13, 2026 | SEC.gov ↗ |
| Research Alliance Corp III | 13G | 14.1% | 1,100,000 | Oct 7, 2026 | SEC.gov ↗ |
| Camping World Holdings, Inc. | 13G amendment | 7.16% | 4,551,055 | Aug 14, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 68 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (3)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (6)
As reported in the adviser's Form ADV filed May 29, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures